People · Operator
Named in public records as an officer, director or promoter · active 2016–2016 · Telecommunications, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Trident Private Holdings III, LLC | — | Telecommunications | Series D+ | $230.3M | $4.6B | 2016 |
| Gemini Therapeutics, Inc. | — | Biotechnology | Seed | $2.0M | $88.8M | 2016 |
James McLaughlin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James McLaughlin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Jean George | 1 | 6 |
| Jeffrey Hendren | 1 | 5 |
| Frank Baker | 1 | 5 |
| Peter Berger | 1 | 5 |
| Jason Rhodes | 1 | 3 |
| Hubert De Pesquidoux | 1 | 3 |
| Robert Aquilina | 1 | 2 |
| Dennis Randolph | 1 | 1 |
| Adam Coyle | 1 | 1 |
| Brett Watson | 1 | 1 |
| Henry Graham | 1 | 1 |
| Matthew Hewitt | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.